Core Viewpoint - The company has received a milestone payment of $5 million from Caldera Therapeutics, triggered by the approval of QX030N/CLD-423 for Phase I clinical trials by the Human Research Ethics Committee [1] Group 1: Clinical Development - The dual antibody QX030N/CLD-423 has been approved by the HREC in Australia and is set to begin clinical trials in early 2026 [1] - The Phase I clinical trial will be randomized, double-blind, placebo-controlled, and dose-escalating, focusing on safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) in healthy adults [1] Group 2: Partnership and Financials - The company signed a licensing agreement with Caldera on April 23, 2025, granting Caldera exclusive global development and commercialization rights for QX030N/CLD-423 [2] - As of December 8, 2025, the company has received a total of $15 million in upfront and milestone payments from Caldera, along with equity in Caldera [2] - The company could receive up to an additional $540 million in future payments based on specific clinical development, regulatory, and commercial milestones, as well as tiered royalties on net sales of QX030N/CLD-423 [2]
荃信生物-B(02509)：QX030N于澳大利亚的I期临床试验获得人类研究伦理委员会许可及收到里程碑付款